Prognostic value of the CALLY index in patients undergoing transcatheter aortic valve implantation.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2026-06-01 Epub Date: 2026-06-23 DOI:10.1080/17520363.2026.2692041

Serkan Aslan, Ali Rıza Demir, Gökhan Demirci, Emre Aydın, Merve Yükselen Aydın, Begüm Uygur, Hicaz Zencirkiran Ağuş, Arda Güler, Serkan Kahraman, Gamze Babür Güler, Mehmet Ertürk

{"title":"Prognostic value of the CALLY index in patients undergoing transcatheter aortic valve implantation.","authors":"Serkan Aslan, Ali Rıza Demir, Gökhan Demirci, Emre Aydın, Merve Yükselen Aydın, Begüm Uygur, Hicaz Zencirkiran Ağuş, Arda Güler, Serkan Kahraman, Gamze Babür Güler, Mehmet Ertürk","doi":"10.1080/17520363.2026.2692041","DOIUrl":null,"url":null,"abstract":"Aims: The C-reactive protein-albumin-lymphocyte (CALLY) index is a composite biomarker reflecting inflammation, nutritional status, and immune response. This study evaluated the association of the CALLY index with all-cause mortality in patients undergoing transcatheter aortic valve implantation (TAVI).Methods: In this retrospective study, 733 consecutive TAVI patients were classified as Low-CALLY (≤0.95) or High-CALLY (>0.95) using an ROC-derived cutoff. The primary endpoint was all-cause mortality during follow-up. Predictors of mortality were assessed using Cox proportional hazards regression, while discriminative performance and survival were evaluated by ROC and Kaplan-Meier analyses.Results: Mortality was higher in the Low-CALLY group than in the High-CALLY group (57.1% vs. 19.3%; p < 0.001). The CALLY index showed moderate discrimination for mortality (AUC 0.719; 95% CI 0.681-0.757; p < 0.001). In multivariable Cox regression, Low CALLY remained independently associated with mortality in the clinical model (HR 3.31; 95% CI 2.49-4.39), STS-PROM-adjusted model (HR 3.16; 95% CI 2.37-4.22), and EuroSCORE II-adjusted model (HR 3.72; 95% CI 2.84-4.88) (all p < 0.001). Kaplan-Meier analysis showed lower survival in the Low-CALLY group (log-rank p < 0.001).Conclusion: The CALLY index was independently associated with mortality after TAVI and may complement established risk scores in pre-procedural risk stratification.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"519-530"},"PeriodicalIF":2.1000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13436832/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2692041","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: The C-reactive protein-albumin-lymphocyte (CALLY) index is a composite biomarker reflecting inflammation, nutritional status, and immune response. This study evaluated the association of the CALLY index with all-cause mortality in patients undergoing transcatheter aortic valve implantation (TAVI).

Methods: In this retrospective study, 733 consecutive TAVI patients were classified as Low-CALLY (≤0.95) or High-CALLY (>0.95) using an ROC-derived cutoff. The primary endpoint was all-cause mortality during follow-up. Predictors of mortality were assessed using Cox proportional hazards regression, while discriminative performance and survival were evaluated by ROC and Kaplan-Meier analyses.

Results: Mortality was higher in the Low-CALLY group than in the High-CALLY group (57.1% vs. 19.3%; p < 0.001). The CALLY index showed moderate discrimination for mortality (AUC 0.719; 95% CI 0.681-0.757; p < 0.001). In multivariable Cox regression, Low CALLY remained independently associated with mortality in the clinical model (HR 3.31; 95% CI 2.49-4.39), STS-PROM-adjusted model (HR 3.16; 95% CI 2.37-4.22), and EuroSCORE II-adjusted model (HR 3.72; 95% CI 2.84-4.88) (all p < 0.001). Kaplan-Meier analysis showed lower survival in the Low-CALLY group (log-rank p < 0.001).

Conclusion: The CALLY index was independently associated with mortality after TAVI and may complement established risk scores in pre-procedural risk stratification.

查看原文本刊更多论文

CALLY指数对经导管主动脉瓣置入术患者的预后价值。

目的：c反应蛋白-白蛋白淋巴细胞（CALLY）指数是反映炎症、营养状况和免疫反应的复合生物标志物。本研究评估了经导管主动脉瓣植入术（TAVI）患者CALLY指数与全因死亡率的关系。方法：在这项回顾性研究中，733例连续TAVI患者被划分为低cally（≤0.95）或高cally（>0.95）。主要终点是随访期间的全因死亡率。死亡率预测因子采用Cox比例风险回归评估，判别性能和生存率采用ROC和Kaplan-Meier分析评估。结果：低CALLY组的死亡率高于高CALLY组（57.1% vs. 19.3%）； p p p p结论：CALLY指数与TAVI术后死亡率独立相关，可补充术前风险分层中已建立的风险评分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.